CITIUS ONCOLOGY, INC.

Citius Oncology, Inc. (Nasdaq: TENK) is a commercial-stage oncology biopharmaceutical company that reached public markets through its de-SPAC merger with TenX Keane Acquisition Corp., a blank-check vehicle sponsored by TenX Keane Acquisition Sponsor LLC that completed its IPO in 2021. The company, which focuses on hematology and oncology therapeutics, holds U.S. commercial rights to LYMPHIR (denileukin diftitox), an FDA-approved treatment for relapsed or refractory cutaneous T-cell lymphoma. Citius Oncology filed a definitive proxy statement (DEF 14A) with the SEC on August 26, 2026, accession number 0001213900-26-093757. Sign up for a SpacDesk account to access the full filing history, merger timeline, and real-time data on TENK.